Technology | Quality Assurance (QA) | July 10, 2019

IBA Launches Monte Carlo Patient QA for Varian Halcyon at AAPM 2019

New SciMoCa Monte Carlo patient QA enables fast and efficient quality assurance accuracy for Varian Halcyon in addition to all other major radiation therapy systems

IBA Launches Monte Carlo Patient QA for Varian Halcyon at AAPM 2019

July 10, 2019 — IBA announced the launch of the latest functionality of the SciMoCa Monte Carlo Patient QA solution at the 61st annual American Association of Physicists in Medicine (AAPM) annual meeting, July 14-18 in San Antonio, Texas. The new release of SciMoCa provides what IBA calls the first and only worldwide commercial Monte Carlo Patient QA for the Varian Halcyon System.

Healthcare professionals can now verify all Halcyon treatment plans independently, accurately, and with an automated and efficient workflow. The fast Monte Carlo dose calculation enables highly accurate results even for the most challenging cases like non-coplanar stereotactic body radiation therapy (SBRT), and in particular for indications with tissue inhomogeneity like lung and head & neck treatments.

Monte Carlo is the gold standard for dose calculation accuracy in treatment planning. With SciMoCa, the accuracy of Monte Carlo is now available for independent secondary dose calculation and patient QA (quality assurance) as well, allowing users to verify the most advanced treatment plans with an equally robust and fast QA solution. SciMoCa is used clinically for all standard linear accelerator (linac) types, for the Accuray CyberKnife and TomoTherapy/Radixact, and is now also compatible with Varian Halcyon.

The high-quality beam models for SciMoCa are created linac-specific for customers applying dedicated processes, expert tools and experience. This process allows an independent verification of the commissioning data and the TPS model, providing an additional level of peace of mind about the accuracy of the machine and TPS commissioning. This is particularly valuable for pre-commissioned treatment machines like Halcyon.

The SciMoCa software is manufactured by Radialogica LLC and globally distributed by IBA Dosimetry.

For more information: www.iba-dosimetry.com

Related Content

Non-oncology doctors’ knowledge of oncology is frequently not up to date, with risks in the communication with patients  

Getty Images

News | Radiation Oncology | September 20, 2021
September 20, 2021 — The rapid pace of developments in the oncology field, mainly brought by cancer immunotherapy, me
IBA (Ion Beam Applications S.A., EURONEXT), a world leader in particle accelerator technology, and SCK CEN (Belgian Nuclear Research Center) announced a strategic R&D partnership to enable the production of Actinimum-225 (225Ac), a novel radioisotope which has significant potential in the treatment of cancer.
News | Radiation Oncology | September 17, 2021
September 17, 2021 — IBA (Ion Beam Applications S.A., EURONEXT), a world leader in particle accelerator technology, a
Evaluation of therapeutic efficacy of drug candidates in preclinical oncology with positron emission tomography (PET)

Getty Images

Feature | PET Imaging | September 14, 2021 | By Todd Sasser, Ph.D.
With a wealth of landmark studies in Breast, Cervical, Melanoma, Prostate, Colorectal, Oesophagus, Endocrine and Lung cancer, the ESMO Congress 2021 is a clear demonstration that oncology research has once again gathered momentum after being temporarily stopped in its tracks by the outbreak of the virus

Getty Images

News | Radiation Oncology | September 13, 2021
September 13, 2021 — At the opening press conference of the ...
Comment letters on the 2022 physician fee schedule and Radiation Oncology Model urge CMS to scale back extreme cuts that jeopardize access to life-saving cancer treatments

Getty Images

News | ASTRO | September 09, 2021
September 9, 2021 — The American Society for Radiation Oncology (AS...

Image of a STING protein, courtesy of UCLA Jonsson Comprehensive Cancer Center

News | PET Imaging | September 08, 2021
September 8, 2021 — A new study from scientists at the UCLA Jonsso...
An artificial intelligence (AI) program can spot signs of lung cancer on computed tomography (CT) scans a year before they can be diagnosed with existing methods, according to research presented at the European Respiratory Society International Congress.

Diagram showing details of the lung screening experiment. Image courtesy of the European Respiratory Society/Benoit Audelan

News | Artificial Intelligence | September 08, 2021
September 8, 2021 — An artificial intell...
At the recent 2021 AAPM Meeting in July, Sun Nuclear Corporation featured its comprehensive portfolio of independent, integrated quality management solutions for radiation therapy and diagnostic imaging.
News | Quality Assurance (QA) | September 02, 2021
September 2, 2021 — At the recent 2021 AAPM Meeting